Navigation Links
Scientists Develop Method to Track Immune System Enzyme in Live Animals

Scientists supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at the National Institutes of Health have created two mouse strains that will permit researchers to trace, in a live animal, the activity of an enzyme believed to play a crucial role both in the normal immune response as well as autoimmunity and B cell tumor development. Their report appears in the Journal of Experimental Medicine.

The enzyme, known as activation-induced cytidine deaminase or AID (which has no relation to the AIDS virus), is expressed by B cells, which are produced in the bone marrow and are responsible for making antibodies that attack foreign invaders such as viruses and bacteria. The enzyme enables the cells to respond with precision to the almost limitless types of invaders the body may encounter. Unfortunately, it also has a down side.

B cells constantly scan the body for foreign invaders, explains Rafael Casellas, Ph.D., an investigator in NIAMS Molecular Immunology and Inflammation Branch and lead author of the paper. As B cells encounter foreign antigens from viruses, bacteria or allergens, they migrate to germinal centers specialized microenvironments in tonsils, spleen and lymph nodes.

Within germinal centers, B cells divide extensively and express the AID enzyme, which causes random mutations and recombination in the cells immunoglobulin (antibody) genes. For the most part, these genetic changes are beneficial because they enable B lymphocytes to attack and stop the invader. In some cases, however, AID-dependent alterations in the genetic material of B cells can also lead to unwanted results such as autoimmunity and development of B cell tumors, as in the case of Burkitt lymphoma.

It becomes crucial that we comprehend how AID is regulated during the normal immune response as well as in tumorigenesis and autoimmunity, says Casellas. The problem with understanding how AID is regu lated or deregulated is that there has not been an easy way to visualize the enzymes action in a living animal until now.

To address this issue, Dr. Casellas and his colleagues created transgenic mice that had a green fluorescent protein derived from jellyfish fused to the AID enzyme. In these transgenic animals, B cells express the tagged enzyme during the immune response.

In a second mouse strain, Casellas and coworkers expressed permanently a yellow fluorescent protein in the progeny of germinal center B cells. Thanks to these new mouse models, we can track in live animals whenever the AID enzyme is active as well as the result of that activity, says Casellas. Scientists can also cross these new mouse strains with mice predisposed to B-cell tumors or autoimmunity to see differences in enzyme expression in health and disease.

NIAMS Director Stephen I. Katz. M.D., Ph.D., believes these new tools have great potential to help solve some mysteries of the immune system, such as the causes of B-cell tumors and autoimmunity. The better we understand these problems, he says, the closer we come to better treatments for them and eventually, perhaps, ways to prevent them.


Related medicine news :

1. Scientists plan human cloning clinic in the United States
2. Scientists found ancient Human Germ Killer
3. Scientists locate key hormone involved in appetite control
4. Scientists open the book of life
5. Scientists review SARS
6. Scientists crack dengue fever puzzle
7. Scientists push to lower hidden sodium in food
8. Indian Scientists Make Wide-Ranging Analysis And Annotation Of X Chromosome
9. Scientists have found effective brain regions for deep brain stimulation for Parkinson’s
10. Scientists reveal the secrets of sarcasm
11. Scientists Unveil Mechanism Behind Resistance to Severe Malaria
Post Your Comments:

(Date:11/30/2015)... , ... November 30, 2015 , ... ... has verified that their Vasont Universal Integrator (VUI) extension unites with Syncro Soft’s ... and managing content as a continuous process with the latest release of oXygen® ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra Medical, Inc. and ... Mesh technology for soft tissue repair in the US via Insightra’s national direct ... surgical mesh intended to support and reinforce soft tissue for 6-9 months before ...
(Date:11/30/2015)... PA (PRWEB) , ... November 30, 2015 , ... ... of the assets of DataTrade Solutions Inc., a Healthcare IT consulting, development and ... utilizing the programming and technical experience available within DataTrade to extend the services ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... Laser Center is one of a select few plastic surgeons in the New ... fat removal. , SculpSure™ is the world’s first heat-induced laser treatment for fat ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... of critical importance to the medical schools of the future. To reach an ... suite at the 2015 ChangeMedEd conference in Chicago, organized by the American Medical ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , November 30, 2015 ... directed at up to 10 G protein-coupled receptor (GPCR) ... ) to research and develop potential new medicines directed ... across multiple therapeutic areas. --> Heptares Therapeutics ... company and wholly-owned subsidiary of Sosei Group Corporation ("Sosei"; ...
(Date:11/30/2015)... Mexico Healthcare and Life Sciences Report 2015 . ... --> Pharmaboardroom releases its new 98-page Mexico Healthcare and ... , a country of over 122 million people. --> ... people. --> It offers companies, investors, policymakers, and stakeholders ... the second largest pharma and healthcare market in Latin ...
(Date:11/30/2015)... and REHOVOT, Israel , Nov. ... pharmaceutical company focused on acquiring and developing innovative therapies ... the appointment of Keith A. Katkin as ... Gregory J. Flesher , chief executive officer for OticPharma, ... successful organizations.  As chairman, he will be able to ...
Breaking Medicine Technology: